vs
FLOTEK INDUSTRIES INC（FTK）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
FLOTEK INDUSTRIES INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$67.5M vs $35.5M），FLOTEK INDUSTRIES INC净利率更高（4.5% vs -304.2%，领先308.7%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 33.0%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 29.3%）
Flotek Industries是一家技术驱动的多元化企业，主要开发和供应特种化学品、高性能材料及相关设备解决方案，服务全球能源、采矿和工业制造领域，助力客户提升运营效率。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FTK vs RXRX — 直观对比
营收规模更大
FTK
是对方的1.9倍
$35.5M
营收增速更快
RXRX
高出648.7%
33.0%
净利率更高
FTK
高出308.7%
-304.2%
两年增速更快
RXRX
近两年复合增速
29.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $67.5M | $35.5M |
| 净利润 | $3.0M | $-108.1M |
| 毛利率 | 22.5% | 59.8% |
| 营业利润率 | 8.9% | -304.8% |
| 净利率 | 4.5% | -304.2% |
| 营收同比 | 33.0% | 681.7% |
| 净利润同比 | -31.7% | 39.6% |
| 每股收益（稀释后） | $0.09 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTKRXRX
| Q4 25 | $67.5M | $35.5M | ||
| Q3 25 | $56.0M | $5.2M | ||
| Q2 25 | $58.4M | $19.2M | ||
| Q1 25 | $55.4M | $14.7M | ||
| Q4 24 | $50.8M | $4.5M | ||
| Q3 24 | $49.7M | $26.1M | ||
| Q2 24 | $46.2M | $14.4M | ||
| Q1 24 | $40.4M | $13.8M |
净利润FTKRXRX
| Q4 25 | $3.0M | $-108.1M | ||
| Q3 25 | $20.4M | $-162.3M | ||
| Q2 25 | $1.8M | $-171.9M | ||
| Q1 25 | $5.4M | $-202.5M | ||
| Q4 24 | $4.4M | $-178.9M | ||
| Q3 24 | $2.5M | $-95.8M | ||
| Q2 24 | $2.0M | $-97.5M | ||
| Q1 24 | $1.6M | $-91.4M |
毛利率FTKRXRX
| Q4 25 | 22.5% | 59.8% | ||
| Q3 25 | 31.7% | -183.8% | ||
| Q2 25 | 24.7% | -4.9% | ||
| Q1 25 | 22.5% | -48.0% | ||
| Q4 24 | 24.2% | -181.4% | ||
| Q3 24 | 18.3% | 53.7% | ||
| Q2 24 | 19.9% | 36.2% | ||
| Q1 24 | 21.8% | 19.1% |
营业利润率FTKRXRX
| Q4 25 | 8.9% | -304.8% | ||
| Q3 25 | 16.2% | -3327.6% | ||
| Q2 25 | 4.4% | -916.8% | ||
| Q1 25 | 10.1% | -1297.9% | ||
| Q4 24 | 10.1% | -4042.4% | ||
| Q3 24 | 5.5% | -377.1% | ||
| Q2 24 | 4.8% | -697.4% | ||
| Q1 24 | 5.2% | -698.4% |
净利率FTKRXRX
| Q4 25 | 4.5% | -304.2% | ||
| Q3 25 | 36.3% | -3135.3% | ||
| Q2 25 | 3.0% | -894.2% | ||
| Q1 25 | 9.7% | -1373.3% | ||
| Q4 24 | 8.7% | -3935.5% | ||
| Q3 24 | 5.1% | -367.5% | ||
| Q2 24 | 4.3% | -676.6% | ||
| Q1 24 | 3.9% | -662.4% |
每股收益（稀释后）FTKRXRX
| Q4 25 | $0.09 | $-0.17 | ||
| Q3 25 | $0.53 | $-0.36 | ||
| Q2 25 | $0.05 | $-0.41 | ||
| Q1 25 | $0.17 | $-0.50 | ||
| Q4 24 | $0.15 | $-0.56 | ||
| Q3 24 | $0.08 | $-0.34 | ||
| Q2 24 | $0.06 | $-0.40 | ||
| Q1 24 | $0.05 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.7M | $743.3M |
| 总债务越低越好 | $40.0M | $9.6M |
| 股东权益账面价值 | $113.1M | $1.1B |
| 总资产 | $220.0M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.35× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资FTKRXRX
| Q4 25 | $5.7M | $743.3M | ||
| Q3 25 | $4.6M | $659.8M | ||
| Q2 25 | $5.0M | $525.1M | ||
| Q1 25 | $6.3M | $500.5M | ||
| Q4 24 | $4.4M | $594.4M | ||
| Q3 24 | $5.0M | $427.6M | ||
| Q2 24 | $4.8M | $474.3M | ||
| Q1 24 | $5.2M | $296.3M |
总债务FTKRXRX
| Q4 25 | $40.0M | $9.6M | ||
| Q3 25 | $40.0M | $11.9M | ||
| Q2 25 | $40.0M | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | $194.0K | — |
股东权益FTKRXRX
| Q4 25 | $113.1M | $1.1B | ||
| Q3 25 | $110.5M | $1.0B | ||
| Q2 25 | $71.8M | $919.1M | ||
| Q1 25 | $119.7M | $933.9M | ||
| Q4 24 | $113.9M | $1.0B | ||
| Q3 24 | $109.0M | $524.6M | ||
| Q2 24 | $106.2M | $584.4M | ||
| Q1 24 | $103.9M | $401.2M |
总资产FTKRXRX
| Q4 25 | $220.0M | $1.5B | ||
| Q3 25 | $212.7M | $1.4B | ||
| Q2 25 | $172.2M | $1.3B | ||
| Q1 25 | $170.2M | $1.3B | ||
| Q4 24 | $170.8M | $1.4B | ||
| Q3 24 | $160.6M | $726.5M | ||
| Q2 24 | $156.0M | $775.9M | ||
| Q1 24 | $155.8M | $557.8M |
负债/权益比FTKRXRX
| Q4 25 | 0.35× | 0.01× | ||
| Q3 25 | 0.36× | 0.01× | ||
| Q2 25 | 0.56× | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.2M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 2.07× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流FTKRXRX
| Q4 25 | $6.2M | $-46.1M | ||
| Q3 25 | $-1.9M | $-117.4M | ||
| Q2 25 | $-4.5M | $-76.4M | ||
| Q1 25 | $7.3M | $-132.0M | ||
| Q4 24 | $-2.6M | $-115.4M | ||
| Q3 24 | $5.1M | $-59.2M | ||
| Q2 24 | $-3.1M | $-82.2M | ||
| Q1 24 | $3.9M | $-102.3M |
自由现金流FTKRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率FTKRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度FTKRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率FTKRXRX
| Q4 25 | 2.07× | — | ||
| Q3 25 | -0.09× | — | ||
| Q2 25 | -2.54× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | -0.58× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | -1.55× | — | ||
| Q1 24 | 2.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTK
| Related Party | $49.6M | 74% |
| Nonrelated Party | $17.9M | 26% |
RXRX
暂无分部数据
